financetom
Business
financetom
/
Business
/
Lincoln Electric Q2 sales beat estimates, to buy rest of Alloy Steel Australia for $90 mln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lincoln Electric Q2 sales beat estimates, to buy rest of Alloy Steel Australia for $90 mln
Jul 31, 2025 4:55 AM

Overview

* Lincoln Electric Q2 2025 sales rise 6.6%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 beats consensus, reflecting strong operational performance

* Co to acquire remaining 65% of Alloy Steel Australia for $90 mln

Outlook

* Lincoln Electric ( LECO ) expects Alloy Steel acquisition to add $0.13-$0.15 EPS annually

Result Drivers

* ORGANIC GROWTH - Co reports a 2.9% increase in organic sales, contributing to overall sales growth

* ACQUISITIONS - A 3.0% sales increase attributed to recent acquisitions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $1.09 $1.04

bln bln (7

Analysts

)

Q2 Beat $2.6 $2.31 (9

Adjusted Analysts

EPS )

Q2 EPS $2.56

Q2 $145.60

Adjusted mln

Net

Income

Q2 Net $143.40

Income mln

Q2 $195.10

Adjusted mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for Lincoln Electric Holdings Inc ( LECO ) is $235.00, about 5% above its July 30 closing price of $223.33

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
First Atlantic Nickel Receives Drilling Permits Over Multiple Zones
First Atlantic Nickel Receives Drilling Permits Over Multiple Zones
Jul 17, 2024
08:48 AM EDT, 07/17/2024 (MT Newswires) -- First Atlantic Nickel Corp. ( FANCF ) on Wednesday said it has received drilling permits for 26 sites for its work and drilling program at the Atlantic Nickel Project in central Newfoundland. The 2024 exploration program currently underway is set to identify and test the most promising awaruite nickel zones along the established...
United Lithium Kicks Off Exploration Programs in Finland
United Lithium Kicks Off Exploration Programs in Finland
Jul 17, 2024
08:47 AM EDT, 07/17/2024 (MT Newswires) -- United Lithium ( ULTHF ) said Wednesday that it commenced the 2024 exploration program in early June on five of its properties in Finland covering 105,000 hectares. The program aims to identify lithium-cesium-tantalum-type pegmatites across the Kietyonmaki project, as well as the Kannus, Kova, Kast and Salkola property reservations. Our exploration efforts will...
BioCardia Receives Patent for Morph DNA Transseptal Delivery
BioCardia Receives Patent for Morph DNA Transseptal Delivery
Jul 17, 2024
08:45 AM EDT, 07/17/2024 (MT Newswires) -- BioCardia ( BCDA ) said Wednesday that it was granted a patent for its method for transseptal access to the heart using a steerable catheter based on the company's Morph DNA technology. The patent issued by the US Patent Office protects the company's products through 2035, BioCardia ( BCDA ) said. BioCardia's (...
Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment
Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment
Jul 17, 2024
08:45 AM EDT, 07/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Wednesday it has received regulatory clearance from the Netherlands' ethics authority to begin human testing of its IMP761 potential autoimmune disease treatment. Immutep ( IMMP ) describes IMP761 as a LAG-3 agonist antibody to potentially treat rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, among other autoimmune diseases....
Copyright 2023-2026 - www.financetom.com All Rights Reserved